About Re-Stem
Re-Stem is a company based in Suzhou (China) founded in 2012 by Benno Jiao. It operates as a B2B and Research and Development. Re-Stem offers products and services including RE-EnableTM, RE-AGN 2.0, RE-KneewTM, and Cell Banking. Re-Stem operates in a competitive market with competitors including Horizon Therapeutics, NuVasive, Ensoma, Osteal Therapeutics and ZetaGen, among others.
- Headquarter Suzhou, China
- Founders Benno Jiao
- SectorsHealthcare
- Email••••••••
- Website restembio.com
- Legal Name บริษัท รีสเต็ม แมเนจเม้นท์ จำกัด
- Date of Incorporation 10 Aug, 1977
- Jurisdiction Maharashtra, India
Associated legal entities of Re-Stem
Re-Stem operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | – | – | – | View details |
Products & Services of Re-Stem
Re-Stem offers a comprehensive portfolio of products and services, including RE-EnableTM, RE-AGN 2.0, RE-KneewTM, and Cell Banking.
Treatment for spinal cord injury recovery through cell-based intervention.
Therapy targeting lung and liver cancers with proprietary technology.
Autologous therapy for knee osteoarthritis using mesenchymal stem cells.
Storage and supply of stem cells for research and enterprises.
People of Re-Stem
1 people are tracked at Re-Stem (1 in leadership).
| Name | Role | Group |
|---|---|---|
Benno Jiao | Founder, CEO | Leadership |
Complete people profiles for Re-Stem
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Re-Stem
Re-Stem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Therapeutics, NuVasive, Ensoma, Osteal Therapeutics and ZetaGen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| nuvasive.com | 1997 | San Diego, United States | $54.1M | 2,450 | Smart surgical devices for spinal surgery are developed. | |
| ensoma.com | 2019 | Boston, United States | $205M | 52 | Provider of in vivo stem cell modification technologies and vector-based drug delivery tool | |
| ostealtx.com | 2013 | San Clemente, United States | $110.8M | – | Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections | |
| zetagen.com | 2017 | Syracuse, United States | $20.35M | – | Small molecule therapeutics for bone regeneration are developed. | |
| angitiabio.com | 2018 | Woodland Hills, United States | $276M | – | Drugs for muscle, bone, and joint diseases are developed. | |
| histogenics.com | 2000 | Waltham, United States | $115.72M | 69 | Restorative cell therapies for orthopedic diseases are developed. | |
| ingeneron.com | 2005 | Houston, United States | $51.4M | – | Advanced cell separation technologies are developed for regenerative cell preparation. | |
| nohlatherapeutics.com | 2015 | Seattle, United States | $120.5M | 48 | Develops stem-cell transplant solutions using umbilical cord blood as an alternative to bone-marrow transplants. |
Detailed competitors of Re-Stem
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Re-Stem
The website of Re-Stem (restembio.com) receives about 680.7K visits a month.
- Monthly visits680.7K
▼ 6.7% vs previous month
Websites whose visitors overlap most with Re-Stem. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| falconebiz.com | 100% | 959.8K | #63,970 | View details | |
| tofler.in | 97% | 556K | #105,509 | View details | |
| zaubacorp.com | 96% | 4.9M | #12,689 | View details | |
| tracxn.com | 92% | 2.9M | #16,597 | View details | |
| indiafilings.com | 90% | 2.1M | #29,959 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Re-Stem
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to Re-Stem
10 companies that operate in the same segment as Re-Stem (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Re-Stem
Re-Stem was founded in 2012.
Re-Stem is headquartered in Suzhou, China. It is registered at Suzhou, Jiangsu, China.
Benno Jiao is the current CEO of Re-Stem. They have also founded this company.
RE-Stem Biotech is a biotechnology company that focuses on researching and developing cell therapies targeting osteoarthritis, spinal cord injury, and various cancers. They utilize a hybrid technology platform for stem cell and immune cell therapies, cell banking, and supplying stem cells to other enterprises. Based in China and Thailand, they collaborate with an international team of scientists and executives. Their activities include creating proprietary treatments like RE-EnableTM and partnering for clinical applications, serving research and medical sectors.
Re-Stem's top competitors include Horizon Therapeutics, NuVasive and Ensoma.
Re-Stem offers RE-EnableTM, RE-AGN 2.0, RE-KneewTM, and Cell Banking.
Re-Stem operates through ,.
The website of Re-Stem receives about 681 thousand visits a month.